Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations has been successfully treated with tyrosine kinase inhibitors (TKIs). However, resistance to osimertinib, a third-generation TKI, can be difficult to overcome in this small subset of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Qian, Qu, Jingjing, Chen, Zhen, Zhou, Jianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674200/
https://www.ncbi.nlm.nih.gov/pubmed/34926262
http://dx.doi.org/10.3389/fonc.2021.760097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674200/
https://www.ncbi.nlm.nih.gov/pubmed/34926262
http://dx.doi.org/10.3389/fonc.2021.760097

Ejemplares similares